Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: GlobeNewswire
Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported its financial results for first quarter ended March 31, 2020 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Despite the global impacts of the COVID-19 pandemic, I am pleased to report exciting progress in both our proprietary and partnered neurology programs. Over the next 12 months, we anticipate a number of important clinical and regulatory milestone events from our pipeline of innovative epilepsy treatments, and we are fortunate to have the cash runway to support our business objectives.” Dr. Pimstone continued, “Looking specifically at our proprietary epilepsy program
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysGlobeNewswire
- Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024GlobeNewswire
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Royal Bank of Canada from $56.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
XENE
Earnings
- 2/29/24 - Beat
XENE
Sec Filings
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- XENE's page on the SEC website